Pfizer and BioNTech have started a trial evaluating an adapted version of their Covid-19 vaccine targeting the Omicron variant of the coronavirus.

So here is the big question for Hal Barron as he departs GlaxoSmithKline: Did he accomplish his mission to turnaround its labs?

Alzheimer's patient groups are planning publicity and lobbying campaigns to protest a Medicare coverage proposal they say could delay the use of new drugs for 10 years.

The Medicines Patent Pool has signed agreements with 27 generic manufacturers to make and supply the Covid-19 pill from Merck to 105 low- and middle-income countries.

A team of biotech veterans have raised $3 billion to create Altos Labs, which will aim to battle disease by reprogramming the fundamental machinery of living cells.

Unilever has signaled it will continue pursuing a blockbuster deal to buy the GlaxoSmithKline consumer health care unit after an earlier offer was rejected.

Desperate to reverse the turmoil surrounding its controversial Alzheimer’s treatment, Biogen has a shopping list of potential acquisitions.

Medicare may have released a plan to restrict access to the controversial Biogen Alzheimer’s drug, but the biggest losers may be other drug makers readying treatments.

Medicare plans to cover the controversial Biogen Alzheimer’s drug, but only for certain patients enrolled in clinical trials.

A preliminary decision on Medicare coverage for the Biogen Alzheimer's drug is due this week, and it has major implications for state Medicaid programs.

More than 65 institutional investors are urging the directors of companies making Covid-19 vaccines to tie executive compensation to vaccine equity.

The organization that negotiates supply contracts on behalf of more than 95% of the nation’s academic hospitals estimates just one to five vials of the Biogen Alzheimer's medicine are ordered…

Three drug makers each donated tens of thousands of dollars last year to Republican members of Congress who voted against certifying President Biden’s election, despite pledges to withhold or pause…

As 2022 gets under way, pharmaceutical companies have so far raised wholesale prices by a median of 4.9% on more than 450 prescription medicines.

For some vaccine makers, the pandemic has generated billions of dollars in profits, but developers of a new vaccine rolling out soon in India are getting zilch.

While physicians of color are more likely to serve marginalized communities, medical training is an intense reenactment of the injustices that seeded marginalization in the first place.

Oxfam America has filed a complaint with securities regulators accusing Moderna of providing “misleading statements” and concealing material information about its dispute with the U.S. government over Covid-19 vaccine patents.

Moderna (MRNA) disclosed that a booster shot of its coronavirus vaccine significantly raises the level of antibodies that can thwart the Omicron variant.

Moderna reported that a third dose of its Covid-19 vaccine increased immune responses against the Omicron coronavirus variant compared with two doses in lab tests.

The FDA permanently removed a controversial restriction on access to abortion pills by allowing patients to receive the medicine by mail.

Biogen expects to begin a large clinical trial next May to confirm the benefits of its Alzheimer’s treatment, pending clearance from the FDA.

Robert Califf escaped largely unscathed from a two-hour hearing vetting him to be U.S. Food and Drug Administration commissioner.

The Pfizer pill to treat Covid-19 retained its 89% efficacy at preventing hospitalization and death in the full results of a study of high-risk patients.

Pfizer has agreed to acquire Arena Pharmaceuticals in a $6.7 billion all-cash deal to expand its cancer and inflammatory disease treatment pipeline.

Anthony Fauci is not convinced Covid-19 vaccine manufacturers are going to need to produce an Omicron-specific version of their vaccines.

Some of the biggest names in biotech venture capital have charged their startups millions of dollars in “consulting fees,” effectively taking back a small portion of the money they invested.

Biogen is preparing for its largest-ever layoff in which more than 1,000 employees are expected to lose their jobs after the disastrous launch of Aduhelm.

GlaxoSmithKline and Vir Biotechnology reported their Covid-19 antibody treatment retained effectiveness against the Omicron variant in laboratory studies.

People who received the Pfizer-BioNTech Covid vaccines may get as much benefit from a J&J booster shot as a Pfizer one.

The FDA is laying the groundwork for the rapid review of Omicron-targeted vaccines and drugs if they turn out to be needed.